Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797864 | 0.93 | CCR4 (0.36) | CCR4KDM4EEPHX2SMN1; SMN2KCNH2 | |
| SCHEMBL15466297 | 0.91 | TSHR (0.37) | KDM4EEPHX2KCNH2MCHR1CYP2C9 | |
| SCHEMBL794556 | 0.90 | PDE5A (0.33) | CCR4EPHX2PTGESTRPV1 | |
| SCHEMBL15466511 | 0.90 | PDE5A (0.34) | CCR4EPHX2 | |
| SCHEMBL794326 | 0.89 | RXFP1 (0.36) | KDM4EEPHX2SMN1; SMN2KCNH2MCHR1 | |
| SCHEMBL798417 | 0.88 | CCR4 (0.35) | CCR4KDM4EEPHX2SMN1; SMN2CYP2C9 | |
| SCHEMBL798197 | 0.82 | PTPN11 (0.33) | CCR4PTGESTRPV1 | |
| SCHEMBL17857812 | 0.82 | NR1H2 (0.35) | CCR4EPHX2PTGES | |
| SCHEMBL15466443 | 0.81 | KCNH2 (0.41) | KDM4EEPHX2KCNH2MCHR1CYP2C9 | |
| SCHEMBL798260 | 0.81 | ATF1 (0.40) | KDM4EEPHX2KCNH2MCHR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9375000-B2 | Pesticidal arylpyrrolidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20140046069-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| EP-2616437-A1 | PESTICIDAL ARYLPYRROLIDINES | Bayer Intellectual Property GmbH (DE) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035011-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046069-A1 | PESTICIDAL ARYLPYRROLIDINES | DDT, ACHE, CAT | CCR4 215/4885KDM4E 856/4885EPHX2 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.